IMC 2032
Alternative Names: IMC-2032Latest Information Update: 03 Aug 2022
At a glance
- Originator ImmuneCyte
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cockayne syndrome
- Preclinical Beta-thalassaemia
Most Recent Events
- 20 Jul 2022 Phase-I clinical trials in Cockayne syndrome in USA, Prior to July 2022 (Immunecyte pipeline, July 2022).)
- 19 Jul 2022 Preclinical trials in Beta-thalassaemia in USA (Parenteral), Prior to July 2022 (Immunecyte pipeline, July 2022)